NUCLEAR MEDICINE AND BIOLOGY
Scope & Guideline
Elevating standards in nuclear medicine and biological research.
Introduction
Aims and Scopes
- Development of Radiopharmaceuticals:
The journal emphasizes research on the synthesis, optimization, and characterization of radiopharmaceuticals, including novel agents for imaging and therapy. - Molecular Imaging Techniques:
There is a strong focus on the advancement of imaging modalities such as PET, SPECT, and hybrid imaging techniques, which are critical for diagnosing and monitoring diseases. - Theranostics:
The integration of diagnostic and therapeutic applications, particularly in the context of targeted radiotherapy and personalized medicine, is a core area of exploration. - Radiochemistry Innovations:
Research that explores new radiochemical methodologies, including novel labeling techniques and automation of synthesis processes, is a significant aspect of the journal. - Preclinical and Clinical Applications:
The journal publishes studies that bridge the gap between laboratory research and clinical applications, showcasing the translational potential of nuclear medicine. - Biomarker Development:
The identification and evaluation of biomarkers for various diseases, particularly cancer, through imaging and radiolabeled compounds are highlighted.
Trending and Emerging
- Targeted Alpha Therapy (TAT):
There is a growing interest in targeted alpha therapy, reflecting advancements in the understanding of radiobiology and the therapeutic potential of alpha-emitting isotopes for cancer treatment. - Artificial Intelligence in Imaging:
The integration of artificial intelligence and machine learning techniques in imaging analysis and radiopharmaceutical development is rapidly emerging as a key focus area. - Bioconjugation Techniques:
Research on bioconjugation strategies for enhancing the delivery and efficacy of radiopharmaceuticals is trending, particularly in the context of antibody-drug conjugates. - Immuno-PET Imaging:
The application of PET imaging with immunoconjugates for monitoring immune responses and cancer therapies is increasingly prominent, reflecting the growing field of immuno-oncology. - Nanoparticle-based Imaging and Therapy:
The use of nanoparticles for targeted imaging and therapy is gaining traction, with studies focusing on their unique properties for enhancing drug delivery and imaging sensitivity. - Radioligand Development for CNS Disorders:
There is an emerging trend in developing radioligands specifically for imaging central nervous system disorders, reflecting the need for better diagnostic tools in neurology.
Declining or Waning
- Traditional Radiopharmaceuticals:
There is a noticeable decline in studies focused on traditional radiopharmaceuticals, as newer, more targeted agents and approaches gain popularity. - Non-targeted Imaging Approaches:
Research on non-targeted imaging methods appears to be waning, as the field increasingly emphasizes precision medicine and targeted imaging agents. - Basic Radiochemistry:
Papers focusing exclusively on basic radiochemistry without applications in imaging or therapy are becoming less frequent, reflecting a trend towards more applied research. - Conventional SPECT Imaging:
The prevalence of conventional SPECT imaging studies has decreased, possibly due to the increasing adoption of PET and hybrid imaging techniques that offer higher sensitivity and resolution. - Invasive Procedures in Imaging:
Research involving invasive imaging procedures has diminished as the focus shifts towards less invasive and more patient-friendly imaging technologies.
Similar Journals
PET Clinics
Pioneering Progress in Positron Emission Tomography.PET Clinics, published by Elsevier Inc, is a premier academic journal focusing on the advancements and applications of Positron Emission Tomography (PET) in various medical fields. With its ISSN 1556-8598 and E-ISSN 1559-7814, the journal has established a strong reputation in the scientific community, reflected in its impressive Q1 quartile rankings in Medicine (miscellaneous), Radiation, and Radiology, Nuclear Medicine, and Imaging for 2023. The journal operates within a well-defined scope that bridges innovative research and practical clinical applications, targeting professionals, researchers, and students keen on the intersection of nuclear medicine and imaging technologies. Although not an open-access journal, PET Clinics ensures accessibility through institutional subscriptions, making valuable insights available to the academic community. With an emphasis on enhancing patient care and treatment outcomes through cutting-edge imaging techniques, this journal serves as an essential resource for those seeking to expand their knowledge and expertise in the rapidly evolving field of PET.
Nuclear Medicine and Molecular Imaging
Transforming Research into Revolutionary Medical SolutionsNuclear Medicine and Molecular Imaging, published by SPRINGER HEIDELBERG, stands as a pivotal platform in the interdisciplinary field of radiology and nuclear medicine, focusing on innovative research and developments from 2010 to 2024. With its ISSN 1869-3474 and E-ISSN 1869-3482, this journal aims to disseminate advanced studies that explore the diagnostic and therapeutic applications of nuclear medicine technologies. Operating from Germany, it has positioned itself in the Q3 category within the Radiology, Nuclear Medicine and Imaging sector, showcasing its relevance among peer journals, with a Scopus rank of #204 out of 333. This journal not only serves as an essential resource for researchers and practitioners eager to stay abreast of modern methodologies and findings but also underscores the crucial advancements in molecular imaging techniques. Although currently not an open-access journal, it doesn't detract from its mission to promote knowledge exchange among academia and the medical community, thus paving the way for innovative solutions and improved patient care in nuclear medicine.
World Journal of Nuclear Medicine
Innovating Diagnostics and Therapies in Nuclear MedicineWorld Journal of Nuclear Medicine, published by THIEME MEDICAL PUBL INC, is a premier peer-reviewed journal dedicated to advancing the field of nuclear medicine. With an Open Access model established since 2011, this journal ensures that high-quality research is accessible to a wide audience, fostering knowledge sharing and collaboration among researchers, clinicians, and students alike. The journal aims to publish innovative studies, reviews, and clinical trials that contribute significantly to both the theoretical and practical aspects of nuclear medicine, enhancing diagnostic and therapeutic techniques within this critical area of healthcare. As the journal continues to grow in visibility and impact, it remains an essential resource for those seeking to stay at the forefront of advancements in nuclear medicine.
EJNMMI Research
Elevating Standards in Radiology and Nuclear Medicine.EJNMMI Research, a prominent journal published by Springer, plays a pivotal role in advancing the fields of radiology, nuclear medicine, and imaging. With an impact factor that reflects its strong standing—ranking in the top 22% of its category (Q1 as of 2023)—this open-access journal offers researchers, professionals, and students unparalleled access to innovative research and developments in the field since its inception in 2011. Based in Germany, EJNMMI Research fosters global collaboration by ensuring that cutting-edge findings are freely accessible, thereby accelerating scientific discovery and application. With an emphasis on high-quality, peer-reviewed articles, it serves as an essential resource for those seeking to stay at the forefront of nuclear medicine and imaging. By bridging theoretical insights with practical applications, the journal not only influences academic discourse but also supports ongoing advancements in clinical practices.
Translational Cancer Research
Empowering cancer research with open access insights.Translational Cancer Research, published by AME Publishing Company in Hong Kong, is a pivotal journal aimed at fostering the advancement of oncology-related knowledge through the dissemination of high-quality research findings. With its ISSN 2218-676X and E-ISSN 2219-6803, this journal serves as a vital resource for researchers, professionals, and students in the fields of Cancer Research, Oncology, and Radiology, Nuclear Medicine, and Imaging. Established in 2012, the journal covers the latest breakthroughs and cross-disciplinary approaches that drive innovation in cancer treatment and diagnostics. Although currently classified in the Q4 Quartile for Cancer Research and Q3 for both Oncology and Radiology, Translational Cancer Research continuously works toward improving its academic influence and impact, evidenced by its ongoing research contributions. The journal emphasizes open access, making crucial research available to a global audience. We invite scholars and industry professionals to engage with the latest findings and discussions within these critical areas of medical science.
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN
Unveiling the Future of Medical ImagingROFO-Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, published by Georg Thieme Verlag KG, is a pivotal journal in the fields of radiology and nuclear medicine, offering invaluable insights for researchers, healthcare professionals, and students alike. With an ISSN of 1438-9029, this journal has been a stalwart of scientific communication since its inception in 1975, actively contributing to advancements in imaging techniques and radiation therapy. Although it operates under traditional access, the journal maintains a respectable standing, reflected by its Q3 ranking in Radiology, Nuclear Medicine and Imaging and Q4 in Medicine (miscellaneous), highlighting its significance in the scholarly community. Its coverage spans a wide array of topics pertinent to diagnostic imaging and therapy protocols, making it an essential resource for anyone seeking to understand the complexities of modern radiological practices. As the journal continues to evolve through 2024, it invites contributions that enrich the dialogue around technological innovations and clinical applications in the realm of imaging modalities.
American Journal of Nuclear Medicine and Molecular Imaging
Advancing the Frontiers of Nuclear Medicine and ImagingThe American Journal of Nuclear Medicine and Molecular Imaging (ISSN: 2160-8407), published by E-CENTURY PUBLISHING CORP, is a distinguished platform for the dissemination of cutting-edge research in the fields of nuclear medicine and molecular imaging. With a commitment to advancing scientific inquiry and clinical applications, this journal serves as a vital resource for researchers, clinicians, and students dedicated to exploring innovative imaging modalities, radiopharmaceuticals, and their applications in diagnosing and treating various medical conditions. Although currently not available as an open-access journal, this publication plays a crucial role in fostering academic dialogue and collaboration within the medical community. Its diverse range of topics and expert contributions underscore its impact in bridging the gap between research findings and clinical practice, making it an essential read for anyone interested in the rapidly evolving landscape of nuclear medicine and imaging technologies.
EJNMMI Radiopharmacy and Chemistry
Elevating standards in nuclear medicine research.EJNMMI Radiopharmacy and Chemistry, published by SpringerNature, stands at the forefront of research in the critical fields of radiopharmacy and nuclear medicine. With an impressive impact factor and a dedicated Open Access policy since 2016, this journal invites the global scientific community to share advancements in the synthesis, development, and application of radiopharmaceuticals within the realm of analytical chemistry and pharmacology. As evidenced by its notable categorizations, including Q1 in Analytical Chemistry and Radiology, Nuclear Medicine and Imaging, along with high Scopus rankings, EJNMMI offers a prestigious platform for rigorous peer-reviewed research that informs and inspires progress in medical imaging and therapeutics. The journal's commitment to accessibility fosters collaboration and innovation, making it an essential resource for researchers, medical professionals, and students seeking to advance their understanding and application of radiopharmaceuticals.
Molecular Imaging
Transforming Insights into Innovations in Imaging.Molecular Imaging is a prominent journal published by SAGE Publications Inc., which serves as a vital platform for the dissemination of high-quality research in the field of molecular imaging. With an E-ISSN of 1536-0121, this journal has established itself within several key areas, including Biomedical Engineering, Biotechnology, Condensed Matter Physics, Molecular Medicine, and Radiology, Nuclear Medicine and Imaging. Spanning from 2002 to 2024 and currently classified within the prestigious Q2 and Q3 quartiles, Molecular Imaging aims to highlight the latest developments and innovative methodologies in molecular imaging techniques and applications. Researchers from diverse backgrounds will find the journal's content valuable for staying updated with recent advancements, evidenced by its competitive Scopus ranking and a commitment to fostering interdisciplinary collaboration. Although the journal is not open access, the rigorous peer-review process ensures that all published articles provide significant contributions to the field, making it an essential resource for professionals, researchers, and students alike.
Theranostics
Transforming Therapeutics through Collaborative Research.Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.